Profiel
Harry S.
Palmin served as President, Chief Executive Officer, and Director at Novelos Therapeutics, Inc. from 2005 to 2013.
He also worked as Chief Financial Officer at Opexa Therapeutics, Inc. In 2022, he became the Chief Financial Officer at Acer Therapeutics, Inc. Mr. Palmin received his undergraduate degree from Brandeis University and his graduate degree from Brandeis International Business School.
Eerdere bekende functies van Harry Palmin
| Bedrijven | Functie | Einde |
|---|---|---|
| ACER THERAPEUTICS INC. | Financieel Directeur/CFO | 17-11-2023 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and provides pharmaceutical drugs | Algemeen Directeur | 01-10-2013 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops autologous personalized cell therapies for the treatment of various diseases. | Financieel Directeur/CFO | - |
Opleiding van Harry Palmin
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Brandeis University
Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and provides pharmaceutical drugs | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops autologous personalized cell therapies for the treatment of various diseases. | Health Technology |
Brandeis International Business School
Brandeis International Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Acer Therapeutics, Inc.
Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes therapies for serious rare and life-threatening diseases | Health Technology |
















